Converting Cox hazard ratios with Cox-TEL to improve interpretation of drug efficacy in checkpoint inhibitor trials

In health, the immune system plays a key role in protecting us not only from infectious disease, but also from the development of cancer; immune cells recognize and destroy harmful agents, whether pathogens or malignant cells.

With cancer, tumor growth begins to outpace immune system activity, as malignant cells accumulate genetic changes that block an effective immune response.

Cancer researchers have long sought a mechanism to combat these anti-immune effects and reactivate the body’s own natural defenses against cancer; these efforts have come to fruition in recent years with the development and FDA approval of immune checkpoint inhibitor (ICI) therapy.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

Byline

Yu Shyr, PhD

Harold L. Moses Chair in Cancer Research, Vanderbilt University School of Medicine; Director, Center for Quantitative Sciences; Director, Vanderbilt Technologies for Advanced Genomics Analysis and Research Design; Associate director for Quantitative Sciences Integration, Ingram Cancer Center; Professor of Biostatistics, Biomedical Informatics, and Health Policy

DOWNLOAD THE PDF

Table of Contents

YOU MAY BE INTERESTED IN

Cancer Policy

Federal judge nixes FDA’s LDT rule, says agency exceeded its authority

A federal judge ruled that the FDA lacks the statutory authority to regulate laboratory developed tests, finding squarely in favor of plaintiffs in the consolidated lawsuits brought by American Clinical Laboratories Association, Association for Molecular Pathology, and others. ASCP submitted an amicus brief supporting the plaintiffs.

April 11, 2025

Vol.51 No.14

Drugs & Targets

FDA approves Vitrakvi for NTRK gene fusion-positive solid tumors

FDA granted full approval for Vitrakvi (larotrectinib), a first-in-class TRK inhibitor for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.

April 11, 2025

Vol.51 No.14

Drugs & Targets

FDA approves Jobevne, a bevacizumab biosimilar

FDA approved Biocon Biologics Ltd’s Jobevne (bevacizumab-nwgd), a biosimilar bevacizumab for intravenous use. Jobevne, a recombinant humanized monoclonal antibody used to treat several different types of cancer, is a biosimilar to the reference product Avastin (bevacizumab).

April 11, 2025

Vol.51 No.14

Conversation with The Cancer Letter

Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy

After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.

In an oral history now taken down by FDA, Andrew von Eschenbach recounts his stint as the head of both FDA and NCI—simultaneously

Credit: NCI/Linda BartlettIn an oral history conducted by FDA in September 2013, Andrew C. von Eschenbach recounted his eight-month stint in a dual role as both FDA acting commissioner and NCI director.

FDA approves durvalumab for muscle invasive bladder cancer

FDA approved AstraZeneca’s durvalumab (Imfinzi) with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent durvalumab as adjuvant treatment following radical cystectomy, for adults with muscle invasive bladder cancer.

April 04, 2025

Vol.51 No.13

Converting Cox hazard ratios with Cox-TEL to improve interpretation of drug efficacy in checkpoint inhibitor trials

YOU MAY BE INTERESTED IN

Federal judge nixes FDA’s LDT rule, says agency exceeded its authority

FDA approves Vitrakvi for NTRK gene fusion-positive solid tumors

FDA approves Jobevne, a bevacizumab biosimilar

Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy

In an oral history now taken down by FDA, Andrew von Eschenbach recounts his stint as the head of both FDA and NCI—simultaneously

FDA approves durvalumab for muscle invasive bladder cancer

Renew today!

Subscriber content

Never miss an issue!

Login